Axonics Modular Technologies

Novel sacral neuromodulation system for treating overactive bladder

Axonics has developed a novel and potentially best-in-class implantable sacral neuromodulation (SNM) system for the treatment of overactive bladder and faecal incontinence.

It will be the smallest fully implantable, and first rechargeable SNM device, and is expected to work in the body for up to 15 years.

CEO  Raymond Cohen

www.axonics.com

Advent Contact  Shahzad Malik

Advent invested in the Series B in 2015.
Exited Investment
3 June 2020 in Axonics, Press Release

Axonics® Announces U.S. Food & Drug Administration Approval of Wireless Patient Remote Control with SmartMRI Technology

Press Release.   June 3, 2020 at 6:00 AM EDT IRVINE, Calif.--(BUSINESS WIRE)--Jun. 3, 2020-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is…
Read More
14 November 2019 in Axonics, Press Release

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System for Urinary Clinical Indications

Press Release.   IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for…
Read More
9 September 2019 in Axonics, Press Release

Axonics® Announces U.S. Food & Drug Administration Approval for its Sacral Neuromodulation System

Press Release.   IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable rechargeable sacral neuromodulation (“SNM”) device…
Read More
22 February 2019 in Axonics, Press Release

Axonics® Granted Expanded CE Mark Label; First and Only Sacral Neuromodulation System Approved for Use with Full-Body MRI Scans

Press Release.   IRVINE, Calif.--(BUSINESS WIRE)--Feb. 22, 2019-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”)…
Read More
31 October 2018 in Axonics, Press Release

Axonics Modulation Technologies, Inc. Announces Pricing of Initial Public Offering of Common Stock

Press Release.   October 31, 2018 IRVINE, Calif.--(BUSINESS WIRE)--Oct. 30, 2018-- Axonics Modulation Technologies, Inc. (“Axonics”), a medical technology company focused on the design, development and commercialization of innovative and…
Read More
2 May 2017 in Axonics, Press Release

Axonics Announces $14.5 Million First Close of Series C Financing

Press Release.   Irvine, CA – May 2, 2017 – Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal…
Read More
21 December 2015 in Axonics, Press Release

Axonics Modulation Technologies Announces $38.5 Million Series B Financing

Press Release.   Irvine, CA – December 21, 2015 – Axonics Modulation Technologies, Inc., developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million…
Read More